PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jbreasthealthThe Journal of Breast Health
 
J Breast Health. 2016 July; 12(3): 102–106.
Published online 2016 July 1. doi:  10.5152/tjbh.2016.3070
PMCID: PMC5351478

Factors that Affect Drain Indwelling Time after Breast Cancer Surgery

Abstract

Objective

The most common procedure to prevent seroma formation, a common complication after breast and axillary surgery, is to use prophylactic surgical drains. Ongoing discussions continue regarding the ideal time for removing drains after surgical procedures. In this study, we aimed to investigate factors that affect drain indwelling time (DIT).

Materials and Methods

From 2014 to 2015, a total of 91 consecutive patients with breast cancer were included in the study. The demographic characteristics of the patients, treatment methods, histopathologic features of the tumor, size of removed breast tissue (BS), tumor size (TS), number of totally removed lymph nodes (TLN), and metastatic lymph nodes (MLN), whether they had neoadjuvant chemotherapy, and the DIT were retrospectively recorded from the hospital database.

Results

The mean age of the patients was 48.9 years, and the mean DIT was 4.8 days. The mean size of breast removed was 17.3 cm and tumor size was 4.7 cm, and the mean number of metastatic lymph nodes was 3.3, and mean total number of lymph nodes was 14.1. Patients who had neoadjuvant chemotherahpy had longer DIT. There was a positive correlation between the BS, TS, TLN, MLN, length of hospital stay, and DIT. Linear regresion analysis revealed that the BS, TLN, and history of neoadjuvant chemotherahpy were independent risk factors for DIT.

Conclusion

DIT primarily depends on BS, TLN, and history of neoadjuvant chemotherahpy. A policy for the management of removing drains to prevent seroma formation should thus be individualized.

Keywords: Breast cancer, mastectomies, drainage, suction

Introduction

Drains offer a significant advantage for seroma after breast cancer surgery (1). Surgical drains are used in the immediate postoperative period because the dead space in the operation area is one of the most important factors for seroma-associated complications (1, 2). Although there are different ways to prevent seroma, including external compression, flap fixation, dead space obliteration (3) or tissue glues (1, 4), closed suction wound drainage has been accepted as the most effective technique in reducing morbidity (57). However, there are several disadvantages of drain insertion such as discomfort and retrograde migration of bacteria (2). According to a meta-analysis, there was no widely accepted consensus for an ideal time for drain removal following breast cancer surgery (8). Drain removal protocols vary enormously from hospital to hospital, even from department to department in the same hospital. Prolonged drainage may prolong hospital stay (9). Some patients refuse to be discharged with drains, because there are difficulties in managing them at home, which may result in wound infection. Early removal of drains has been linked with shorter length of hospital stay (LOS) (911). However, indiscriminate withdrawal of drains, regardless of the fluid volume of fluid drained, may be accompanied by increased seroma formation (9, 1117). Therefore, repeated aspirations and even surgical draining may be required. Furthermore, the risk of infection, skin flap necrosis, prolonged hospital stay, and delay in the commencement of chemotherapy or radiotherapy, or both in some cases, are often increased if drains are not used (9, 11).

Drain indwelling time (DIT) has not been an issue in many centers for patients who are admitted in the early stages of cancer. However, 40% of the patients at our center are admitted with stage 3 disease and as such a common solution for this problem is still pending. There are many benefits to short-duration drains; however, early withdrawal complications and DIT are very important to know. We believe the knowledge of the factors that affect DIT is the most important step in determining the optimal time. Therefore, the need to investigate the ideal time for drain removal is warranted. The first step is to investigate factor(s) that affect DIT. Accordingly, we aimed to determine these factors in this study.

Materials and Methods

The study was conducted from 2013 to 2014. Ninety-one consecutive patients with breast cancer were admitted to Faculty of Medicine, Department of General Surgery, and were included in the study. All procedures adhered to the ethical principles of the Helsinki Declaration. In order to identify factors that affect DIT, the demographic and tumor features of the patients management strategy, pathologic results of the tumor, the size of removed breast tissue (BS), tumor size (TS), the number of totally-removed lymph nodes (TLN) and metastatic lymph nodes (MLN), whether they had neoadjuvant chemotherapy, LOS, and DIT were retrospectively recorded from the hospital database. The greatest dimension was used for breast size and tumor size. The number of TLN and MLN was assessed using the final histopathologic report.

According to our unit protocols, all drains were removed after fifteen days regardless of the drainage volume, or when the drainage volume was less than 50 mL on two sequential days. If patients were discharged with the drain, they were seen every two days. If fluid collected after drain removal it was removed through percutaneous aspiration.

Statistical analysis

Statistical Package for the Social Sciences package program 18 (SPSS Inc.; Chicago, IL, USA) was used for statistical analysis. After preliminary analysis for factors affecting DIT, multivariate linear regression analysis was used to identify independent risk factors. p<0.05 was accepted as statistically significant.

Results

The study consisted of 91 women with a mean age of 48.9 years (range, 26–81 years); the mean DIT was 4.8 days (range, 0–13 days). The mean BS was 17.3±8.5 cm and TS was 4.73±2.948 cm, and the mean MLN was 3.3 (range, 0–19). The mean TLN was 14.1 (range, 2–32) and LOS was 5.93 days (range, 1–20 days). The rate of patients treated with neoadjuvant chemotherapy was 22/91 (24.18%). The mean DIT was 3.72±2.36 in the patients who had neoadjuvant chemotherapy and 8.18±2.86 in the others. The patients who had neoadjuvant chemotherapy had longer DIT (p<0.001).

There was a positive correlation between the BS, TS, TLN, and MLN, LOS, and DIT (Table 1). Linear regression analysis was performed for the statistically significant variable in the univariate analysis. Linear regression analysis revealed that the BS, TLN, and neoadjuvant chemotherapy used were independent risk factors for DIT (Table 2).

Table 1
Correlation coefficients between drain indwelling time and studied variables
Table 2
Linear regression analysis of independent risk factors of drain indwelling time

The effects of age, histopathologic type, hormone receptor status, concomitant disease on DIT were not statistically significant.

Discussion and Conclusion

The most common complication following breast cancer surgery is seroma, with an incidence of up to 90%. Seroma can lead to several problems including pain, delayed wound healing, skin necrosis, and infections if it remains untreated. It has been suggested that suction drainage markedly decreased the development of postsurgical seroma (10). Furthermore, it has been reported that nearly all of the total seroma formation was drained within the 48 hours of the post-operative period (1, 9). Interestingly, the levels of seroma showed wide variation between the trials. The rates were reported as 21% to 49% for early drain removal regimens, whereas 4% to 28% for late drain removal (8). Andeweg et al. (14) showed that short-term axillary drainage was related to a higher incidence of seroma. However, a similar number of aspirations were needed in the short- and long-term drainage groups with a similar volume per patient requiring aspiration.

The timing of drain removal was reported to have no influence on seroma formation (1, 11, 14, 18, 19). Moreover, no significant difference was demonstrated in the rates of infection between early and late drain removal (8, 18, 2023). All these studies show that DIT is a very controversial issue. One reason for planning this study was that there is no consensus about DIT. We think that the consensus should begin by finding factors that affect DIT. Age, remains a controversial factor because some studies revealed apparent seroma formation, whereas others did not show a significant link, like in our study (10, 11, 2429).

In our clinical practice, we used closed suction drainage systems that are removed from skin flaps following from axilla. Dead space forming after excision is eliminated by the negative pressure applied by the drain. Thus, apposition of skin flaps is promoted and wound healing is strengthened. Negative pressure may decrease wound dehiscence, necrosis, infection and seroma formation as well (4, 10, 30, 31). Closed suction drainage systems seem to be more successful than open drainage systems (32).

First, the drain of the mastectomy skin flaps was removed. The axillary drain remained and continued to drain (1).

Various factors might affect seroma formation. Axillary dissection is related to the formation of postoperative seroma (33). The development of a seroma has been reported in 10% to 52% of cases (9, 34). If a great number of lymph nodes were dissected from the axilla, much more seromas were observed. The higher lymph node yield might be considered as an indirect measure of a more extensive axillary dissection in patients with seroma (1). The amount of drainage may project the extent of injury to the lymph vessels (13). As such, tissue ligation around the axillary vessels during dissection may decrease the amount of postoperative discharge compared with transection with a knife or diathermy (23). The number of lymph nodes remains a controversial factor because some authors declared obvious seroma formation, whereas others did not observe a significant relation (10, 11, 2429). However, the number of lymph nodes removed during axillary dissection was found to be an independent risk factor for the duration of draining in the present study.

Sentinel lymph node biopsy (SLNB) is a minimally-invasive alternative technique to axillary dissection. SLNB has significantly lower seroma formation rates compared with axillary dissection (10, 3537). It also prevents the damage to blood and lymphatic vessels by reducing the need for larger dissection (10). In this study, DIT was lower in patients who were SLNB negative, some of them even had no drainage performed. However, these benefits were reached only if SLNB results were benign; our patients were admitted in the later stages and benefit was limited.

Another factor is the presence of metastatic lymph nodes (9, 32, 38, 39). The number of metastatic lymph nodes remains controversial because some studies found significant seroma formation, and others showed an insignificant association, similar to our study (10, 11, 2429).

Breast size is another important factor (9, 32, 38, 39). Wide chest wall dissection influences seroma formation (14). Breast size was not found to have a significant influence on seroma formation in some studies (40, 41). Extensive dissection causes damage to more blood and lymphatic vessels and subsequently results in larger seroma formation. More seroma is seen in modified radical mastectomy than in simple mastectomy or wide local excision plus axillary lumpectomy (7, 10, 2527). When MRM was compared with breast-conserving surgery (BCS), although the results were mixed, MRM had an overall higher seroma formation (10, 4245). There were correlations between removed breast size and DIT in the present study. Therefore, we found that smaller surgery corresponded with lower DIT. Studies showed that patients who underwent MRM had higher risk of developing seroma than patients who underwent BCS or completed axillary clearance (11, 19, 29). Some studies showed that tumor size had no significant influence on seroma formation (10, 40, 41). In the present study, there was a correlation between tumor size and DIT, but it was not found as an independent risk factor.

Diabetes mellitus was not found as a significant influence on seroma formation (10, 40, 41) and hypertension was significant in influencing factors for seroma formation (10, 36). In our study, neither disease had a significant effect on DIT.

Neoadjuvant chemotherapy used was an independent risk factor for DIT in our study, but other studies determined that this form of chemotherapy had no significant influence on seroma formation (10, 40, 41).

The limitations of our study include: 1. Surgical factors, including technique (surgeon A versus surgeon B), extent of dissection (total mastectomy vs. modified radical mastectomy), surgical devices used for dissection (electrocautery vs. scalpel), these were not investigated; 2. The study would have benefitted if it included patient characteristics such as body mass index and body weight.

Drain indwelling time should be individualized to prevent seroma formation. DIT primarily depends on BS, TLN, and which neoadjuvant chemotherapy is used.

Footnotes

Ethics Committee Approval: Ethics committee approval was received due to the retrospective nature of this study.

Informed Consent: Verbal informed consent was obtained from patients who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - Ö.U.; Design - Ö.U., M.G.; Supervision - Ö.U, A.T.; Funding - Ö.U., M.G.; Materials - Ö.U., Ş.K.; Data Collection and/or Processing - M.G.; Analysis and/or Interpretation - Ö.U., M.G., Z.B.; Literature Review - Ö.U.; Writer - Ö.U., M.G.; Critical Review - M.G., H.G.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

References

1. Barwell J, Campbell L, Watkins RM, Teasdale C. How long should suction drains stay in after breast surgery with axillary dissection? Ann R Coll Surg Engl. 1997;79:435–437. [PMC free article] [PubMed]
2. Kosins AM, Scholz T, Cetinkaya M, Evans GR. Evidence-based value of subcutaneous surgical wound drainage: the largest systematic review and meta-analysis. Plast Reconstr Surg. 2013;132:443–450. http://dx.doi.org/10.1097/PRS.0b013e3182958945. [PubMed]
3. Furrer M, Inderbitzi R, Nachbur B. [Does administration of fibrin glue prevent development of lymphoceles after radical lymphadenectomy?]. Chirurg. 1993;64:1044–1049. [PubMed]
4. Coveney EC, O’Dwyer PJ, Geraghty JG, O’Higgins NJ. Effect of closing dead space on seroma formation after mastectomy--a prospective randomized clinical trial. Eur J Surg Oncol. 1993;19:143–146. [PubMed]
5. Ezeome ER, Adebamowo CA. Closed suction drainage versus closed simple drainage in the management of modified radical mastectomy wounds. S Afr Med. 2008;98:712–715. [PubMed]
6. Moss JP. Historical and current perspectives on surgical drainage. Surg Gynecol Obstet. 1981;152:517–527. [PubMed]
7. Aitken DR, Hunsaker R, James AG. Prevention of seromas following mastectomy and axillary dissection. Surg Gynecol Obstet. 1984;158:327–330. [PubMed]
8. Kelley TA, Thomson DR, Furniss D. When should axillary drains be removed post axillary dissection? A systematic review of randomised control trials. Surg Oncol. 2012;21:247–251. http://dx.doi.org/10.1016/j.suronc.2012.05.002. [PubMed]
9. Thomson DR, Sadideen H, Furniss D. Wound drainage after axillary dissection for carcinoma of the breast. Cochrane Database Syst Rev. 2013;10:CD006823. http://dx.doi.org/10.1002/14651858.cd006823.pub2. [PubMed]
10. van Bemmel AJ, van de Velde CJ, Schmitz RF, Liefers GJ. Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. Eur J Surg Oncol. 2011;37:829–835. http://dx.doi.org/10.1016/j.ejso.2011.04.012. [PubMed]
11. Hashemi E, Kaviani A, Najafi M, Ebrahimi M, Hooshmand H, Montazeri A. Seroma formation after surgery for breast cancer. World J Surg Oncol. 2004;2:44. http://dx.doi.org/10.1186/1477-7819-2-44. [PMC free article] [PubMed]
12. Cameron AE, Ebbs SR, Wylie F, Baum M. Suction drainage of the axilla: a prospective randomized trial. Br J Surg. 1988;75:1211. http://dx.doi.org/10.1002/bjs.1800751222. [PubMed]
13. Tadych K, Donegan WL. Postmastectomy seromas and wound drainage. Surg Gynecol Obstet. 1987;165:483–487. [PubMed]
14. Andeweg CS, Schriek MJ, Heisterkamp J, Roukema JA. Seroma formation in two cohorts after axillary lymph node dissection in breast cancer surgery: does timing of drain removal matter? Breast J. 2011;17:359–364. http://dx.doi.org/10.1111/j.1524-4741.2011.01099.x. [PubMed]
15. Droeser RA, Frey DM, Oertli D, Kopelman D, Baas-Vrancken Peeters MJ, Giuliano AE, Dalberg K, Kallam R, Nordmann A. Volume-controlled vs no/short-term drainage after axillary lymph node dissection in breast cancer surgery: a meta-analysis. Breast. 2009;18:109–114. http://dx.doi.org/10.1016/j.breast.2009.02.003. [PubMed]
16. O’Hea BJ, Ho MN, Petrek JA. External compression dressing versus standard dressing after axillary lymphadenectomy. Am J Surg. 1999;177:450–453. http://dx.doi.org/10.1016/S0002-9610(99)00089-6. [PubMed]
17. Unalp HR, Onal MA. Analysis of risk factors affecting the development of seromas following breast cancer surgeries: seromas following breast cancer surgeries. Breast J. 2007;13:588–592. http://dx.doi.org/10.1111/j.1524-4741.2007.00509.x. [PubMed]
18. Baas-Vrancken Peeters MJ, Kluit AB, Merkus JW, Breslau PJ. Short versus long-term postoperative drainage of the axilla after axillary lymph node dissection. A prospective randomized study. Breast Cancer Res Treat. 2005;93:271–275. http://dx.doi.org/10.1007/s10549-005-5348-7. [PubMed]
19. Jain PK, Sowdi R, Anderson AD, MacFie J. Randomized clinical trial investigating the use of drains and fibrin sealant following surgery for breast cancer. Br J Surg. 2004;91:54–60. http://dx.doi.org/10.1002/bjs.4435. [PubMed]
20. Inwang R, Hamed H, Chaudary MA, Fentiman IS. A controlled trial of short-term versus standard axillary drainage after axillary clearance and iridium implant treatment of early breast cancer. Ann R Coll Surg Engl. 1991;73:326–328. [PMC free article] [PubMed]
21. Dalberg K, Johansson H, Signomklao T, Rutqvist LE, Bergkvist L, Frisell J, Liljegren G, Ambre T, Sandelin K. A randomised study of axillary drainage and pectoral fascia preservation after mastectomy for breast cancer. Eur J Surg Oncol. 2004;30:602–609. http://dx.doi.org/10.1016/j.ejso.2004.03.020. [PubMed]
22. Ackroyd R, Reed MWR. A prospective randomized trial of the management of suction drains following breast cancer surgery with axillary clearance. The Breast. 1997;6:271–274. http://dx.doi.org/10.1016/S0960-9776(97)90003-5.
23. Kopelman D, Klemm O, Bahous H, Klein R, Krausz M, Hashmonai M. Postoperative suction drainage of the axilla: for how long? Prospective randomised trial. Eur J Surg. 1999;165:117–1120. discussion 121–122. http://dx.doi.org/10.1080/110241599750007289. [PubMed]
24. Petrek JA, Peters MM, Nori S, Knauer C, Kinne DW, Rogatko A. Axillary lymphadenectomy. A prospective, randomized trial of 13 factors influencing drainage, including early or delayed arm mobilization. Arch Surg. 1990;125:378–382. http://dx.doi.org/10.1001/archsurg.1990.01410150100018. [PubMed]
25. Bryant M, Baum M. Postoperative seroma following mastectomy and axillary dissection. Br J Surg. 1987;74:1187. http://dx.doi.org/10.1002/bjs.1800741239. [PubMed]
26. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE. American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–3663. http://dx.doi.org/10.1200/JCO.2006.07.4062. [PubMed]
27. Randolph LC, Barone J, Angelats J, Dado DV, Vandevender DK, Shoup M. Prediction of postoperative seroma after latissimus dorsi breast reconstruction. Plast Reconstr Surg. 2005;116:1287–1290. http://dx.doi.org/10.1097/01.prs.0000181517.20122.36. [PubMed]
28. Schuijtvlot M, Sahu AK, Cawthorn SJ. A prospective audit of the use of a buttress suture to reduce seroma formation following axillary node dissection without drains. Breast. 2002;11:94–96. http://dx.doi.org/10.1054/brst.2001.0366. [PubMed]
29. Gonzalez EA, Saltzstein EC, Riedner CS, Nelson BK. Seroma formation following breast cancer surgery. Breast J. 2003;9:385–388. http://dx.doi.org/10.1046/j.1524-4741.2003.09504.x. [PubMed]
30. Somers RG, Jablon LK, Kaplan MJ, Sandler GL, Rosenblatt NK. The use of closed suction drainage after lumpectomy and axillary node dissection for breast cancer. A prospective randomized trial. Ann Surg. 1992;215:146–149. http://dx.doi.org/10.1097/00000658-199202000-00009. [PubMed]
31. Morris AM. A controlled trial of closed wound suction. Br J Surg. 1973;60:357–359. http://dx.doi.org/10.1002/bjs.1800600509. [PubMed]
32. Pogson CJ, Adwani A, Ebbs SR. Seroma following breast cancer surgery. Eur J Surg Oncol. 2003;29:711–717. http://dx.doi.org/10.1016/S0748-7983(03)00096-9. [PubMed]
33. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Giuliano A, Harris JR, O’Malley F, Schnitt SJ, Singletary SE, Winchester DP. American College of Radiology; American College of Surgeons; Society of Surgical Oncology; College of American Pathology. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin. 2002;52:277–300. http://dx.doi.org/10.3322/canjclin.52.5.277. [PubMed]
34. McCaul JA, Aslaam A, Spooner RJ, Louden I, Cavanagh T, Purushotham AD. Aetiology of seroma formation in patients undergoing surgery for breast cancer. Breast. 2000;9:144–148. http://dx.doi.org/10.1054/brst.1999.0126. [PubMed]
35. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ. Randomized multicenter trial of sentinel node biopsy versus standardaxillary treatment in operable breast cancer: the ALMANAC Trial. J NatlCancer Inst. 2006;98(9):599–609. Erratum in: J Natl Cancer Inst 2006;98:876. http://dx.doi.org/10.1093/jnci/djj158. [PubMed]
36. Burak WE, Jr, Goodman PS, Young DC, Farrar WB. Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin. J Surg Oncol. 1997;64:27–31. [PubMed]
37. Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, Duffy SW. Morbidity after sentinel lymph node biopsy in primarybreast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312–4321. http://dx.doi.org/10.1200/JCO.2005.03.228. [PubMed]
38. Kuroi K, Shimozuma K, Taguchi T, Imai H, Yamashiro H, Ohsumi S, Saito S. Pathophysiology of seroma in breast cancer. Breast Cancer. 2005;12:288–293. http://dx.doi.org/10.2325/jbcs.12.288. [PubMed]
39. Stehbens WE. Postmastectomy serous drainage and seroma: probablepathogenesis and prevention. ANZ J Surg. 2003;73:877–880. http://dx.doi.org/10.1046/j.1445-2197.2003.02832.x. [PubMed]
40. Say CC, Donegan W. A biostatistical evaluation of complicationsfrom mastectomy. Surg Gynecol Obstet. 1974;138:370–376. [PubMed]
41. Woodworth PA, McBoyle MF, Helmer SD, Beamer RL. Seroma formation after breast cancer surgery: incidence and predicting factors. Am Surg. 2000;66:444–450. discussion 450–451. [PubMed]
42. Petrek JA, Peters MM, Cirrincione C, Thaler HT. A prospective randomized trial of single versus multiple drains in the axilla after lymphadenectomy. Surg Gynecol Obstet. 1992;175:405–409. [PubMed]
43. Abe M, Iwase T, Takeuchi T, Murai H, Miura S. A Randomized Controlled Trial on the Prevention of Seroma after Partial or Total Mastectomy and Axillary Lymph Node Dissection. Breast Cancer. 1998;5:67–69. http://dx.doi.org/10.1007/BF02967417. [PubMed]
44. Lumachi F, Brandes AA, Burelli P, Basso SM, Iacobone M, Ermani M. Seroma prevention following axillary dissection in patients with breast cancer by using ultrasound scissors: a prospective clinical study. Eur J Surg Oncol. 2004;30:526–530. http://dx.doi.org/10.1016/j.ejso.2004.03.003. [PubMed]
45. Medl M, Mayerhofer K, Peters-Engl C, Mahrhofer P, Huber S, Buxbaum P, Sevelda P, Leodolter S. The application of fibrin glue after axillary lymphadenectomy in the surgical treatment of human breast cancer. Anticancer Res. 1995;15:2843–2845. [PubMed]

Articles from The Journal of Breast Health are provided here courtesy of Turkish Federation of Breast Diseases Societies